Pluripotency factors regulate definitive endoderm specification through eomesodermin

Adrian Kee Keong Teo,^{1,2} Sebastian J. Arnold,³ Matthew W.B. Trotter,¹ Stephanie Brown,¹ Lay Teng Ang,¹ Zhenzhi Chng,^{1,2} Elizabeth J. Robertson,⁴ N. Ray Dunn,^{2,5} and Ludovic Vallier^{1,5,6}

¹Laboratory for Regenerative Medicine, University of Cambridge, Cambridge CB2 0SZ, United Kingdom; ²Institute of Medical Biology, A*STAR (Agency for Science, Technology, and Research), Singapore 138648; ³Renal Department, Centre for Clinical Research, University Medical Centre, 79106 Freiburg, Germany; ⁴Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom

Understanding the molecular mechanisms controlling early cell fate decisions in mammals is a major objective toward the development of robust methods for the differentiation of human pluripotent stem cells into clinically relevant cell types. Here, we used human embryonic stem cells and mouse epiblast stem cells to study specification of definitive endoderm *in vitro*. Using a combination of whole-genome expression and chromatin immunoprecipitation (ChIP) deep sequencing (ChIP-seq) analyses, we established an hierarchy of transcription factors regulating endoderm specification. Importantly, the pluripotency factors NANOG, OCT4, and SOX2 have an essential function in this network by actively directing differentiation. Indeed, these transcription factors control the expression of *EOMESODERMIN* (*EOMES*), which marks the onset of endoderm specification. In turn, *EOMES* interacts with SMAD2/3 to initiate the transcriptional network governing endoderm formation. Together, these results provide for the first time a comprehensive molecular model connecting the transition from pluripotency to endoderm specification during mammalian development.

[**Keywords:** pluripotency factors; Nanog; definitive endoderm; Eomes; Activin/Nodal signaling; human embryonic stem cells]

Supplemental material is available for this article.

Received October 25, 2010; revised version accepted December 20, 2010.

Gastrulation in mammals marks the specification of the three germ layers (ectoderm, mesoderm, and endoderm) from which all adult tissues are derived. The molecular mechanisms controlling the early formation of these cell types are of major interest to regenerative medicine, since guided differentiation of pluripotent stem cells toward these lineages represents the first milestone toward the generation of clinically useful cell types. Genetic studies in model systems have identified key signaling pathways and transcription factors (TFs) that control specification of the germ layers (Arnold and Robertson 2009). However, the availability of human embryonic stem cells (hESCs) (Thomson et al. 1998) and, more recently, mouse epiblast stem cells (mEpiSCs) (Brons et al. 2007; Tesar et al. 2007) provides new opportunities to expand our understanding of the molecular mechanisms underlying early lineage

allocation, especially in humans, where embryonic material is limited.

hESCs are pluripotent stem cells derived from blastocysts and have the property to proliferate indefinitely *in vitro* while maintaining the capacity to differentiate into derivatives of all three germ layers (Thomson et al. 1998; Reubinoff et al. 2000). Importantly, our group and others have shown that hESCs share a common pluripotent state with mEpiSCs (Brons et al. 2007; Tesar et al. 2007; Greber et al. 2010). This stage corresponds embryonically to the epiblast epithelium prior to primitive streak (PS) formation and the production of mesoderm and definitive endoderm (DE). Thus, hESCs and mEpiSCs are likely representatives of the last pluripotent state before gastrulation.

DE has attracted increasing attention, since key organs for regenerative medicine (such as the pancreas and liver) originate from this germ layer. Extensive studies have shown that DE specification and differentiation are controlled by specific TFs, including Eomesodermin (Eomes), Mixl1, Sox17, and Foxa2 (Dufort et al. 1998; Hart et al. 2002; Kanai-Azuma et al. 2002; Arnold et al. 2008). Nascent DE is marked by *Sox17* and *Foxa2* coexpression,

⁵These authors contributed equally to this work.

⁶Corresponding author.

E-MAIL lv225@cam.ac.uk; FAX 44-1223-747475.

Article published online ahead of print. Article and publication date are online at <http://www.genesdev.org/cgi/doi/10.1101/gad.607311>.

and genetic studies in the mouse have shown that absence of these TFs impairs DE development without directly affecting the formation of the PS. Conditional loss of the T-box TF *Eomes* in the epiblast shows an even earlier phenotype, with cells failing to undergo the epithelial–mesenchymal transition (EMT) required to form mesoderm and DE (Arnold et al. 2008). Consequently, *Eomes* mutants lack expression of early DE markers such as *Hex*, *Cerberus* (*Cer*), and *Foxa2*. In addition, functional studies have identified extracellular factors such as Activin/Nodal that are necessary to induce and maintain the transcriptional network characterizing DE cells in vivo and in differentiating pluripotent stem cells (Vincent et al. 2003; D'Amour et al. 2005). However, our knowledge concerning the interactions between Activin/Nodal signaling and the TFs directing DE specification remains limited. Indeed, very few endoderm markers have been shown to be directly controlled by SMAD2/3, the main intracellular effectors of Activin/Nodal signals. Furthermore, recent studies have shown that Activin/Nodal signaling maintains the pluripotent status of hESCs, human induced pluripotent stem cells (hiPSCs), and mEpiSCs by the positive regulation of *NANOG*, which in turn blocks neuroectoderm differentiation induced by FGF signaling (Xu et al. 2008; Vallier et al. 2009a; Greber et al. 2010). Genetic studies in the mouse have shown that similar events could occur in the pregastrula embryo (Mesnard et al. 2006). The mechanisms by which Activin/Nodal signaling can achieve these two apparently opposite functions of maintaining pluripotency and inducing differentiation remain elusive.

Here, we used hESCs as an in vitro model to investigate the molecular mechanisms controlling the transition from the pluripotent state to specification of DE. We developed and validated a culture system allowing for the efficient differentiation of hESCs into DE cells. Next, we performed a combination of gene expression profiling and gene knock-down and overexpression studies to identify the TFs controlling the initial steps of DE specification. While the pluripotency factors *OCT4* and *SOX2* counteract DE differentiation of hESCs, *NANOG* is necessary to initiate the expression of *EOMES*, which in turn cooperates with SMAD2/3 to activate the transcriptional network directing DE formation. In addition, *EOMES* limits the expression of mesoderm markers. The relevance of our approach in hESCs was further confirmed and our results validated using both mEpiSCs and *Eomes* mutant mouse embryos. In summary, these results reveal that the core pluripotency factors *OCT4*, *SOX2*, and *NANOG* control germ layer specification by regulating the activity of *EOMES*, which governs the bulk of the transcriptional network directing the transition from pluripotency to differentiation within the PS.

Results

Differentiation of hESCs into DE in vitro mimics embryonic development

We recently developed a culture system to drive differentiation of hESCs, hiPSCs, and mEpiSCs into a nearly

homogenous population of DE cells (Vallier et al. 2009b,c; Touboul et al. 2010). This method is based on a chemically defined medium (CDM-ABFLY) supplemented with Activin, BMP4, FGF2, and the PI3K inhibitor LY294002 (Fig. 1A). To further validate this culture system, we established detailed gene expression profiles during the first 3 d of differentiation (Fig. 1B; Supplemental Table 1). Markers specific for the PS of the gastrulating mouse embryo—such as *EOMES*, *MIXL1*, *BRACHYURY*, *WNT3*, and *PDGFRA*—were up-regulated on day 1. Day 2 was marked by a modest decrease in *BRACHYURY* levels and a concomitant increase in the expression of *GOOSECOID* and *LHX1*, which identify endodermal progenitors, and the bona fide DE marker *SOX17*. Day 3 coincided with a further increase in the expression of *SOX17* and another DE marker, *FOXA2*, with ~90% of cells positive by FACS for the cell surface DE marker *CXCR4* (Fig. 1C). Expectedly, hESC colonies grown in these culture conditions appear to undergo EMT, as evidenced by the overt change in colony morphology (Fig. 1A) and dynamic expression of *E-CADHERIN* and *N-CADHERIN* (Fig. 1D; Thiery and Sleeman 2006). Our microarray data were corroborated by quantitative PCR (qPCR) (Fig. 1D), immunostaining (Fig. 1E), and Western blot (Supplemental Fig. 1). Taken together, these results show that DE differentiation of hESCs emulates DE formation in vivo, including the transition through an intermediate stage resembling formation of the PS.

Dynamic expression of NANOG, OCT4, and SOX2 during endoderm specification

Gene expression profiling also revealed that the key pluripotency markers *NANOG*, *OCT4*, and *SOX2* displayed specific patterns of expression during in vitro DE formation. *SOX2* expression strongly decreased after 1 d of differentiation, followed by *NANOG* after 2 d and *OCT4* after 3 d (Fig. 1B; Supplemental Table 1). qPCR and Western blot analyses reinforced these observations, showing that *SOX2* levels decreased as early as 12 h after the onset of differentiation, while *OCT4* and *NANOG* were maintained for an additional 12 h (Figs. 1D, 2A; Supplemental Fig. 1). Interestingly, *EOMES*, *MIXL1*, *BRACHYURY*, and *GOOSECOID* expression was induced after 8 h, indicating that pluripotency and PS markers significantly overlap during the earliest stage of DE formation. Immunostaining confirmed that *NANOG* and *OCT4* colocalize with *EOMES* and *BRACHYURY* in differentiating cells (Fig. 2B). *NANOG* protein levels decreased within the first 24 h of differentiation, which coincided with the peak increase in PS markers, and was no longer detectable after an additional 24 h of culture (Fig. 1E; Supplemental Fig. 1). Finally, *OCT4* decreased only after 48 h of differentiation, concomitant with the induction of *SOX17* (Fig. 1E; Supplemental Fig. 1).

To validate these in vitro observations, we closely examined the expression of *Nanog*, *Oct4*, and *Sox2* in the gastrulating mouse embryo at embryonic day 7.5 (E7.5). As reported previously (Avilion et al. 2003), *Sox2* expression marks presumptive neuroectoderm and is excluded from the posterior PS (Fig. 2C). *Nanog* expression is prominent

Figure 1. Robust differentiation of hESCs into DE. (A) Organization of hESC colonies during DE differentiation in CDM-ABFLY. Bar, 200 μ m. (B) Microarray gene expression heat map of hESCs (five biological replicates) grown for 3 d in CDM-ABFLY (up-regulation in red, down-regulation in green). (C) The percentage of cells determined by FACS that are positive for the cell surface DE marker CXCR4 after 3 d of differentiation. (D) Expression of pluripotency (*NANOG*, *OCT4*, and *SOX2*), epithelial and mesenchymal (*E-CADHERIN* and *N-CADHERIN*), PS (*EOMES*, *MIXL1*, *BRACHYURY*, and *GOOSECOID*), DE (*SOX17*), primitive endoderm (*SOX7*), and neuroectoderm (*GBX2*, *SOX1*, and *PAX6*) markers in differentiating hESCs over 3 d. All error bars indicate standard deviation of three biological replicates. (E) Immunostaining for pluripotency (*NANOG* and *OCT4*), PS (*EOMES*), and DE (*SOX17* and *FOXA2*) markers after 3 d of differentiation. Bar, 50 μ m. See also Supplemental Figure 1.

in epiblast cells entering the PS (Morkel et al. 2003; Hart et al. 2004), while *Oct4* is expressed more broadly throughout the epiblast, the PS, embryonic mesoderm, and nascent endoderm (Fig. 2C; Downs 2008). The persistence of *Oct4* and *Nanog* transcripts in the region of the PS therefore aligns well with our observations that *OCT4* and *NANOG* perdure as DE emerges in vitro, and supports the hypothesis that pluripotency factors do not solely prevent germ layer differentiation, but participate in its specification.

Decrease in OCT4 and SOX2 expression allows endoderm marker gene expression in hESCs, while NANOG is necessary for the specification of pluripotent stem cells toward the endoderm lineage

We next evaluated the function of *NANOG*, *OCT4*, and *SOX2* by gain- and loss-of-function approaches. First, using shRNA-mediated knockdown, we reduced *OCT4* levels in undifferentiated hESCs and observed a decrease in *BRACHYURY* and little variation in *MIXL1* expression, suggesting that *OCT4* does not block PS marker expression. This result is consistent with our observation that

OCT4 and *BRACHYURY* are still coexpressed in hESCs grown for 24 h in endoderm-promoting conditions (Fig. 2B). However, *OCT4* knockdown resulted in increased levels of *GOOSECOID*, *SOX17*, *FOXA2*, *GATA4*, and *GATA6* (Fig. 2D), suggesting that *OCT4* normally suppresses DE genes. Similarly, reduced *SOX2* levels resulted in increased expression of PS and DE markers (Fig. 2E). Conversely, in sh*NANOG*-hESCs, we observed that the basal levels of PS and DE markers decreased (Fig. 2F), implying that *NANOG* normally stimulates rather than inhibits their transcriptional activity.

We then performed a series of reciprocal experiments by overexpressing *OCT4*, *SOX2*, and *NANOG*. Isolating hESCs overexpressing *OCT4* was, however, impossible (data not shown), suggesting that increased *OCT4* levels are incompatible with self-renewal and/or pluripotency (Niwa et al. 2000). To bypass this limitation, we generated a Tamoxifen (4-OHT)-inducible form of *OCT4* (*OCT4-ERT2*) and successfully derived *OCT4-ERT2*-expressing subclones. These were then grown in CDM-ABFLY for 3 d in the presence or absence of 4-OHT. qPCR analyses showed that *OCT4* overexpression was not sufficient to

Figure 2. NANOG, OCT4, and SOX2 control DE specification. (A) Expression of pluripotency (NANOG, OCT4, and SOX2) and PS (EOMES, MIXL1, BRACHYURY, and GOOSECOID) markers during the first 12 h of differentiation. (*) $P < 0.05$ when compared with undifferentiated hESCs. (B) Colocalization of NANOG and OCT4 with EOMES and BRACHYURY in hESCs grown for 12 and 24 h in CDM-ABFLY. Bar, 50 μ m. (C) Expression of *Nanog*, *Oct4*, and *Sox2* in day 7.5 wild-type and mutant embryos in which the *Eomes* gene is specifically deleted from the epiblast with Sox2-Cre (indicated as Eomes^{N/CA}; Sox2-Cre). (D,E,F) Expression of pluripotency (NANOG, OCT4, and SOX2), PS (MIXL1, BRACHYURY, and GOOSECOID) and DE (SOX17, FOXA2, GATA4, and GATA6) markers in hESCs knocked down for OCT4 (D), SOX2 (E), or NANOG (F). (G) Expression of pluripotency (NANOG, OCT4, and SOX2), PS (MIXL1, BRACHYURY, and GOOSECOID) and DE (SOX17 and FOXA2) markers in hESCs overexpressing hrGFP or NANOG. All error bars indicate standard deviation of three biological replicates. See also Supplemental Figure 2.

either maintain the expression of pluripotency markers or block the expression of PS genes (Supplemental Fig. 2A). However, OCT4 overexpression significantly decreased the expression of DE markers, confirming our loss-of-function experiments showing that OCT4 is sufficient to restrain DE specification but is insufficient to abolish its induction. In contrast, constitutive expression of SOX2 was unable to block endoderm differentiation (Supplemental Fig. 2B). Finally, gain-of-function experiments showed that NANOG was sufficient to induce the expression of PS markers (Fig. 2G; data not shown) and appeared to block the expression of endoderm markers in hESCs. This finding supports our recent result that NANOG can limit the inductive effect of Activin/Nodal signaling on endoderm differentiation (Vallier et al. 2009a). Taken together, these data suggest that OCT4 and SOX2 cooperate with additional pluripotency factors to block PS induction and endoderm differentiation, while NANOG plays an active role in the induction of PS genes and the control of DE marker expression.

EOMES is among the first genes induced upon endoderm differentiation and is regulated by NANOG, OCT4, and SOX2

We reasoned that pluripotency factors influence DE specification through two potential mechanisms: by either (1) directly controlling the entire transcriptional network directing DE specification (for example, regulating PS and DE genes such as MIXL1, SOX17, and FOXA2 simultaneously) or (2) controlling the expression of key regulators that are necessary and sufficient for DE induction. In a previous study combining chromatin immunoprecipitation (ChIP) and DNA promoter arrays, Boyer et al. (2005) identified NANOG-, OCT4-, and SOX2-binding sites within a broad number of genes known to be involved in germ layer specification in pluripotent hESCs (Supplemental Table 2). However, these genes represent only a small fraction of those up-regulated upon endoderm differentiation (Fig. 1B;

Supplemental Table 1). This limited overlap therefore favors the second scenario, whereby pluripotency factors cooperate to control only a specific subset of the DE transcriptional network.

Specifically, NANOG, OCT4, and SOX2 were shown to bind cooperatively to two genes (*EOMES* and *GOOSECOID*) that encode TFs known to be expressed in the PS of the gastrulating mouse embryo (Fig. 1B; Boyer et al. 2005). Importantly, these observations do not preclude that pluripotency factors could bind additional factors that have not been shown to be expressed in the PS. Nevertheless, our data show that *EOMES* levels quickly elevate within the first 8 h of in vitro endoderm differentiation, while *MIXL1*, *BRACHYURY*, and *GOOSECOID* levels significantly increase only after 12 h (Fig. 2A). Moreover, genetic studies in the mouse have shown that *Eomes* is essential for DE specification (Arnold et al. 2008), while *Goosecooid* is entirely dispensable (Rivera-Perez et al. 1995). These observations therefore support the hypothesis that pluripotency factors control DE specification by directly regulating *EOMES* expression.

ChIP confirmed that NANOG, OCT4, and SOX2 associate physically with the *EOMES* enhancer region, with persistent binding of NANOG and OCT4 for at least 24 h

after the start of differentiation and the induction of *EOMES* expression (Fig. 3A). Knockdown of either *OCT4* or *SOX2* in hESCs led to an increase in *EOMES* expression, while *NANOG* knockdown significantly decreased it (Fig. 3B). In contrast, *NANOG* overexpression increased *EOMES* levels in hESCs, while *SOX2* overexpression had little effect (Fig. 3C). *OCT4* overexpression did result in a limited increase in *EOMES* expression, suggesting that *OCT4* is not sufficient to block *EOMES* and/or it could also have a positive effect on *EOMES* induction (Lunde et al. 2004).

The positive regulation of *EOMES* expression by NANOG was further confirmed using luciferase assays that monitor the transcriptional activity of an ~1 kb region of the h*EOMES* enhancer region (Fig. 3D). Consistent with *OCT4* overexpression in hESC (Fig. 3C), *OCT4* activation of the *EOMES* reporter was limited. Finally, qPCR analyses revealed that knockdown of *NANOG* expression in hESCs differentiating into DE strongly diminished the expression of PS markers during the first and second day, with decreased expression of DE markers the following 2 d (Fig. 3E; data not shown). Taken together, these results provide strong evidence that *NANOG* has an essential function during DE specification, possibly mediated by the early induction of *EOMES*.

Figure 3. *EOMES* expression is regulated by pluripotency factors during DE specification. (A) ChIP-qPCR analyses show the presence of NANOG, OCT4, and SOX2 on the *EOMES* enhancer region in hESCs over 3 d of differentiation. (B,C) Expression of *EOMES* in hESCs knocked down for *OCT4*, *SOX2*, or *NANOG* (B), and in hESCs overexpressing *GFP*, *OCT4*, *SOX2*, or *NANOG* (C). (D) Luciferase assay showing the effect of *NANOG*, *OCT4*, or *SOX2* overexpression on the transcriptional activity of the *EOMES* enhancer region in hESCs. (*) $P < 0.01$ when compared with hrGFP. (E) Expression of PS (*EOMES*, *MIXL1*, *BRACHYURY*, and *GOOSECOID*) and DE (*SOX17* and *FOXA2*) markers in shScrambled-hESCs or shNANOG-hESCs grown in CDM-ABFLY for 1 and 3 d, respectively. All error bars indicate standard deviation of three biological replicates. See also Supplemental Figure 2.

To strengthen these observations, we performed the reciprocal experiment by stably overexpressing *EOMES* in hESCs. Increased levels of *EOMES* were, however, incompatible with pluripotency and/or self-renewal (data not shown). We therefore generated a Tamoxifen-inducible form of *EOMES* (*EOMES*-ERT2) and introduced it into hESCs. Treatment of these cells with 4-OHT in culture conditions maintaining pluripotency resulted in increased expression of DE markers (*SOX17* and *FOXA2*), with decreased *BRACHYURY* levels (Fig. 4D). The increase in DE marker expression was limited, suggesting that additional cofactors or longer activation are required for *EOMES* to fully induce their expression. Together, these observations demonstrate that *EOMES* is necessary but not fully sufficient for DE specification in vitro, and that its essential function is thus conserved between humans and mice (Arnold et al. 2008).

EOMES controls a large part of the transcriptional network that directs DE formation

To further define the mechanism by which *EOMES* controls DE specification, we comprehensively identified *EOMES* target genes by ChIP in combination with deep sequencing (ChIP-seq). These experiments were performed on hESCs grown for 2 d in CDM-ABFLY in order to capture early regulatory events leading to DE formation. These analyses revealed that >47,016 genomic regions were bound by *EOMES* (Supplemental Table 4A) and 11,309 genes were located in proximity to *EOMES*-binding sites (Supplemental Table 4B). ChIP-qPCR of selected genomic regions corroborated these binding events (Fig. 5A; Supplemental Table 4A). In addition, *EOMES*-binding sites were more frequently located close to the transcriptional start site (TSS) of candidate target genes (Fig. 5B). Gene ontology (GO) analysis revealed that genes bound by *EOMES* are frequently related to molecular processes associated with development (Supplemental Fig. 4A). Finally, motif enrichment analyses showed that a significant number of genomic regions contained the T-box core

motif TCACACCT known to be bound by *EOMES* (Fig. 5C; Conlon et al. 2001). Genes bound by *EOMES* included those characteristically expressed in the PS (*EOMES* itself, *MIXL1*, *BRACHYURY*, *GOOSECOID*, *TBX6*, *FGF8*, *SNAI1*, *SPRY2*, *SPRY4*, *WNT3*, *WNT3A*, and *NODAL*), mesoderm (*BRACHYURY*, *MEOX1*, *TBX6*, *KDR*, *FOXC1*, *ISL1*, and *PDGFRA*) and endoderm (*SOX17*, *CXCR4*, *LHX1*, *FOXA1*, *FOXA2*, and *FOXA3*) (Fig. 5A; Supplemental Table 4B). *EOMES* also bound genomic regions containing microRNAs (miRNAs) (Supplemental Table 4C), including *miR-302* (Supplemental Fig. 4B), which has been shown to have an essential function during endoderm formation in hESCs and *Xenopus* embryos (Rosa et al. 2009). Knockdown of *EOMES* expression during endoderm differentiation resulted in a strong decrease in *miR-302* expression, suggesting that the presence of *EOMES* on the promoter of *miR-302* is functional (Supplemental Fig. 4C). Thus, *EOMES* may also control miRNAs that modulate the activity of key endoderm regulators such as Activin/Nodal signaling (Martello et al. 2007).

In an effort to establish which *EOMES*-binding sites are indeed functional, we defined the number of candidate

Figure 5. *EOMES* governs much of the transcriptional network characterizing endoderm cells. (A) ChIP-qPCR confirms the presence of *EOMES* protein on genes encoding known regulators of endoderm and mesoderm specification. (B) Relative position of the genomic regions bound by *EOMES* to the TSS of candidate target genes. (C) The T-box-binding motif TCACACCT is inferred from a selection of 1000 well-occupied *EOMES*-bound regions identified using ChIP-seq. (D) Fraction of candidate target genes cobound by *EOMES* and *SMAD2/3*. (E) Distance between *EOMES*-bound regions and the nearest *SMAD2/3*-bound regions when both factors bind the same target gene. (F) Representative view of *EOMES*- and *SMAD2/3*-binding sites within the *EOMES* and *MIXL1* genomic loci. The Y-axis depicts the agglomerated read counts within contiguous 200-base-pair windows. (*) Enriched genomic regions that are statistically significant (false discovery rate 5%). (G) Successive ChIP showing the presence of *SMAD2/3* and then *EOMES* on the promoter of DE genes. All error bars indicate standard deviation of three biological replicates. See also Supplemental Figure 4.

target genes up-regulated and down-regulated during endoderm differentiation of shEOMES-hESCs (Supplemental Table 4D,E). This analysis revealed that 1610 candidate target genes were up-regulated and 1814 candidate target genes were down-regulated in the absence of EOMES, indicating that 29.3% (3424 of 11,691 probes) of the binding sites identified by ChIP-seq are likely of functional significance. These observations also supported a role for EOMES in directly limiting mesoderm differentiation, since a broad number of mesoderm genes bound by EOMES showed increased expression upon *EOMES* knockdown (*BRACHYURY*, *SFR*, *MEOX1*, *PDGFRA*, *KDR*, *HAND1*, *GATA4*, and *MYL4*) (Supplemental Table 4D). Finally, similar computational analyses were performed using the gene expression profile of day 3 wild-type DE cells (Supplemental Table 1) to define the total number of genes that are bound by EOMES. This analysis revealed that EOMES bound 75.4% (2292 of 3038, $q < 0.001$) of the genes up-regulated (Supplemental Table 5A) and 79.5% (2336 of 2940, $q < 0.001$) of the genes down-regulated (Supplemental Table 5B) during endoderm differentiation. Taken together, these data suggest that EOMES acts as a “master regulator” of endoderm specification by activating a broad part of the transcriptional network controlling endoderm differentiation and possibly by repressing genes governing mesoderm specification.

EOMES cooperates with Activin/Nodal signaling to control endoderm differentiation

Studies in the mouse and frog have shown that EOMES cooperates with Activin/Nodal signaling during endoderm differentiation (Arnold et al. 2008; Picozzi et al. 2009). To explore this relationship more thoroughly, we first validated the importance of Activin/Nodal signaling in our in vitro system using the potent Activin type I receptor inhibitor SB431542 (Inman et al. 2002). Inhibition of Activin/Nodal signaling during endoderm differentiation abolished the expression of *EOMES* and DE markers (Supplemental Fig. 4D). We next took advantage of ChIP-seq analyses recently performed in our laboratory to detect the binding sites of SMAD2/3, which represent the principal intracellular effectors of Activin/Nodal signaling (S Brown, in prep.). Combining these data and our EOMES ChIP-seq data revealed that EOMES and SMAD2/3 share 3431 target genes (Fig. 5D,F; Supplemental Table 6A,B). The binding sites for EOMES and SMAD2/3 are localized within 1 kb (Fig. 5E) of 74.1% (2541 of 3431) of these candidate target genes (Supplemental Table 6A). Interestingly, 46.1% (1172 of 2541) of these candidate genes were up-regulated or down-regulated upon endoderm differentiation, suggesting that colocalization of EOMES and SMAD2/3 is functionally important (Supplemental Table 6C). Finally, successive SMAD2/3-EOMES ChIP-qPCR analyses showed that EOMES and SMAD2/3 are in the same protein complexes that bind the promoter regions of *EOMES*, *MIXL1*, *GOOSECOID*, *SOX17*, and *FOXA2* (Fig. 5G). Taken together, these results show that Activin/Nodal signaling induces EOMES expression, which in turn cooperates directly with SMAD2/3 during in vitro DE differentiation.

EOMES inhibits the expression of pluripotency markers upon differentiation

Our ChIP-seq analyses also revealed that EOMES binds the promoters of *NANOG*, *OCT4*, and *SOX2* (Supplemental Table 4A). We thus investigated the potential function of these binding events. First, ChIP-seq results were confirmed by examining the presence of EOMES on the promoters of *NANOG*, *OCT4*, and *SOX2* in hESCs and during DE differentiation. ChIP-qPCR showed that EOMES occupied pluripotency gene promoters after 1 and 2 d of differentiation (Fig. 6A), during the time when their expression is decreasing. This suggests that EOMES contributes to the reduction in their transcriptional activity during DE specification. In support of this, *EOMES* overexpression in hESCs decreased *OCT4* and *SOX2* expression (Fig. 6B).

We next explored this regulatory relationship in vivo. We took advantage of the *Eomes* conditional mouse mutant that allows for the specific deletion of *Eomes* within the epiblast, thereby avoiding the early lethality at implantation (Russ et al. 2000; Arnold et al. 2008). Whole-mount in situ hybridization (WISH) revealed that, in the E7.5 gastrulating embryo, *Nanog*, *Oct4*, and *Sox2* expression (Fig. 2C) was not ostensibly changed in the absence of *Eomes*. Interestingly, mutant embryos failed to down-regulate *Nanog* and *Oct4* at subsequent developmental stages (Figs. 2C [E7.75], 6C [E9.5]). Therefore, loss of *Eomes* in the epiblast appears to prolong the expression of pluripotency markers beyond their expected down-regulation during gastrulation. Knockdown of *EOMES* in hESCs was, however, insufficient to maintain the expression of pluripotency markers during DE differentiation (Supplemental Fig. 3D), implying that additional factors block the expression of *NANOG*, *OCT4*, and *SOX2* in vitro. In summary, these observations suggest that EOMES participates in a negative feedback loop that inhibits pluripotency genes during differentiation, thereby allowing progression toward the endodermal fate.

EOMES function in hESCs is conserved in mEpiSCs

The absence of an in vivo model for human development renders it difficult to validate our in vitro results. As an alternative, we examined *EOMES* function using mEpiSCs, which are the in vitro equivalent of the pluripotent epiblast and thus represent a relevant model for germ layer specification. qPCR (Supplemental Fig. 5A) and immunostaining (Supplemental Fig. 5B) of mEpiSCs grown in CDM-ABFLY confirmed that our endoderm differentiation culture system works equally well with mEpiSCs (Vallier et al. 2009c). In particular, we observed that *Eomes* is up-regulated when pluripotency marker levels are still high (Supplemental Fig. 5A; data not shown). Overexpression of EOMES-ERT2 in mEpiSCs also decreased pluripotency markers and induced only a limited increase in PS and endoderm markers (Supplemental Fig. 5C), demonstrating that, similar to hESCs, *EOMES* negatively regulates pluripotency markers without being sufficient to increase the transcriptional activity of genes involved in DE specification.

We next analyzed the evolutionary conservation of newly identified human EOMES-binding regions using

Teo et al.

Figure 6. EOMES controls the expression of pluripotency markers during DE differentiation, and its function in hESCs is conserved in the gastrulating mouse embryo. (A) ChIP-qPCR analyses showing the presence of EOMES protein on pluripotency genes in hESCs grown for 3 d in CDM-ABFLY. (B) Expression of *NANOG*, *OCT4*, and *SOX2* in EOMES-ERT2-hESCs grown for 3 d $\pm$ 4-OHT. (*) $P < 0.05$ when compared with -4-OHT condition. All error bars indicate standard deviation of three biological replicates. (C,D) Expression of *Nanog*, *Oct4*, and *Sox2* (C), and DE (*Sox17* and *Fzd8*) and mesoderm (*Igfbp3*, *HoxB1*, *FoxC1*, *PDGFR α* , *Agtr1*, and *Pcdh19*) (D) markers in wild-type and Eomes^{N/CA}; Sox2-Cre mutant embryos. See also Supplemental Figure 5.

sequence alignment of 16 species. This analysis revealed that EOMES binding was conserved above background (Supplemental Fig. 4E). We then performed ChIP-qPCR on selected EOMES-binding sites using mEpiSCs grown for 2 d in endoderm-promoting culture conditions. These analyses revealed that EOMES bound the same key DE and mesoderm genes in mouse cells (Supplemental Fig. 5D), reinforcing the hypothesis that EOMES governs a major part of the transcriptional network controlling DE differentiation during mouse development.

EOMES organizes germ layer differentiation in the gastrulating mouse embryo

We next performed WISH to define the expression of newly identified EOMES target genes in wild-type and Eomes mutant mouse embryos (Arnold et al. 2008). Consistent with prior findings, conditional loss of Eomes in the epiblast prevents DE formation, as evidenced by the absence of cardinal DE markers such as *Sox17* and *Fzd8* (Fig. 6D). At E7.5, Eomes mutants also show increased expression of mesoderm genes *Igfbp3* and *Hoxb1*, which

were up-regulated upon knockdown of EOMES in vitro (Figs. 4B, 6D; Supplemental Table 3). These results reinforce the hypothesis that EOMES limits mesoderm differentiation and favors DE formation. However, we also observed that the mouse homologs of some genes such as *AGTRL1* and *PCDH19*, which were up-regulated in differentiating shEOMES-hESCs (Supplemental Table 3; data not shown), could not be detected in Eomes mutant embryos (Fig. 6D). Others were observed at reduced levels, such as *Foxc1* and *PDGFR α* (Fig. 6D), revealing some divergence between data generated using hESCs and data obtained in vivo. Nevertheless, these genes are expressed in mesoderm in wild-type embryos, confirming that genes up-regulated upon knockdown of EOMES in vitro are mesoderm markers in vivo. This demonstrates that our in vitro system can be used successfully to study native molecular mechanisms and also identify novel genes involved in germ layer specification.

Discussion

Here, we show that hESCs and mEpiSCs can be used to model endoderm specification, and that combining these

in vitro systems with genetic studies in the mouse represents a powerful approach to address the molecular mechanisms controlling germ layer specification in mammals. We specifically investigated the earliest molecular events operating as epiblast cells shed their pluripotency and engage a transcriptional program controlling commitment to mesoderm or DE lineages. Our results are consolidated into the model presented in Figure 7. OCT4, SOX2, and some unknown factor(s) ("X") cooperate in hESCs and the pluripotent epiblast to block the expression of PS and DE genes, including *EOMES* (Fig. 7A). As DE specification unfurls, inductive signals decrease the expression of inhibitors of differentiation, beginning with *SOX2*, whose expression rapidly shifts anteriorly (Fig. 7B). The absence of *SOX2* allows NANOG–SMAD2/3 complexes (Vallier et al. 2009a) to initiate the expression of *EOMES*, which in turn further represses the expression of pluripotency markers necessary to maintain NANOG. As differentiation progresses, *NANOG* levels continue to decline, allowing interaction between SMAD2/3 and *EOMES* and culminating in the

activation of much of the endoderm transcriptional network. Our data indicate that *EOMES* preferentially directs PS cells toward a DE fate, while simultaneously blocking the expression of mesoderm genes (Fig. 7C). Thus, *EOMES* provides a vital mechanistic link between pluripotency and differentiation.

Our results clearly establish an inhibitory role for OCT4 and SOX2 in DE specification. However, neither *SOX2* nor *OCT4* expression is sufficient to block DE differentiation of hESCs, suggesting the existence of additional differentiation inhibitors (Fig. 7A, "X"). Interestingly, OCT4 has been shown to interact directly with SOX2 to control the expression of pluripotency genes in mouse embryonic stem cells (mESCs) (Chew et al. 2005). Therefore, OCT4–SOX2 complexes could repress the expression of key endoderm regulators such as *EOMES*. However, we were never able to co-overexpress *OCT4-ERT2* and *SOX2* in hESCs (data not shown). Furthermore, very few DE genes are simultaneously bound by OCT4 and SOX2 (Supplemental Table 2), excluding the possibility that SOX2 cooperates directly with OCT4 to restrain the entire network governing endoderm differentiation. Interestingly, our gene expression profiling analysis identified several genes that are down-regulated like *SOX2* after the initiation of endoderm differentiation. These include *DPPA4* and *KLF4* (Supplemental Table 1). Therefore, some of these additional factors may also intervene during DE specification. Moreover, our group previously demonstrated that SIP1 inhibits DE differentiation by limiting the positive effect of Activin/Nodal signaling on endoderm gene expression in hESCs (Chng et al. 2010). *SIP1* expression is repressed by OCT4, NANOG, and SMAD2/3, but is activated by SOX2. Therefore, we propose that down-regulation of *SOX2* upon differentiation provokes a corresponding decrease in *SIP1* expression, which in turn allows elevated Activin/Nodal signaling to promote DE formation.

This hypothesis raises questions about the identity of the signaling pathway that inhibits *SOX2* expression and induces DE. An obvious candidate is BMP, since genetic studies have demonstrated that BMP receptors are necessary for proper DE specification during gastrulation (Davis et al. 2004). In addition, BMP4 is sufficient to inhibit expression of *SOX2* in hESCs grown in defined culture conditions (data not shown). Importantly, inhibition of BMP signaling upon DE differentiation decreased the expression of a broad number of DE markers (Touboul et al. 2010), while addition of BMP4 in defined culture conditions is sufficient to induce the expression of PS markers such as *MIXL1* and *BRACHYURY*. Therefore, BMP signaling could have a key function in DE specification not only by decreasing *SOX2* expression, but also by collaborating with Activin/Nodal signaling to induce the expression of PS and DE genes.

Another important finding from the present work is the novel role of *NANOG* during DE specification. Pluripotency factors are usually considered as inhibitors of differentiation, and our results show that *NANOG* participates actively in DE differentiation by promoting the expression of PS markers such as *EOMES*. Previous studies have shown that *NANOG* limits the expression of neuroectoderm markers induced by FGF signaling in hESCs (Vallier

Figure 7. Model depicting the transition from pluripotency to endoderm specification during mammalian development. (A) Oct4, Sox2, Nanog, and unknown pluripotency factor(s) ("X") repress *EOMES* expression in undifferentiated hESCs and the pregastrula mouse epiblast (around E6). (B) With formation of the posterior PS, *Sox2* expression rapidly shifts to the anterior epiblast (neuroectoderm) and is similarly rapidly down-regulated in differentiating hESCs (Figs. 1,2). Thus, *Sox2* no longer binds the *EOMES* enhancer region. *Nanog* expression within the PS activates *Eomes*, possibly in collaboration with Oct4 (dotted line), which is also broadly expressed in the PS at this stage. (C) *Eomes* then interacts with Smad2/3 to initiate DE differentiation while repressing mesoderm genes.

et al. 2009a). Similar mechanisms may operate during DE specification. Consequently, *NANOG* could have a passive but necessary function in protecting PS cells against neuroectoderm specification. However, *NANOG* binds a vast number of genes involved in DE specification (Supplemental Table 2), and *NANOG* overexpression systematically increases their expression (Fig. 2G). Furthermore, *NANOG* directly interacts with SMAD2/3 in hESCs (Xu et al. 2008), and knockdown of *NANOG* systematically blocks the expression of SMAD2/3 target genes, including PS markers (Vallier et al. 2009a). *NANOG* constitutive expression also limits the transcriptional activity associated with SMAD2/3 and blocks the positive effect of Activin/Nodal signaling on endoderm gene expression (Vallier et al. 2009a). Therefore, *NANOG* likely acts to fine-tune Activin/Nodal signaling, allowing expression of PS genes while avoiding premature induction of DE. Two key in vivo experiments that will aid in the refinement of *NANOG* function in the PS and during DE formation are to conditionally inactivate *Nanog* in the mouse epiblast and to assess the prevalence of endodermally derived lineages in teratomas generated from *Nanog*-deficient mESCs.

Intriguingly, our results appear to contradict a previous study showing that *Eomes* controls DE specification indirectly through *Mixl1* (Izumi et al. 2007). In their study, Izumi et al. (2007) did not perform the ChIP-seq analyses necessary to validate their observations. Most of their conclusions are based on gain-of-function analyses, which can be difficult to interpret with T-box TFs because overexpression can result in nonspecific artificial transcriptional activation. Importantly, our loss-of-function studies combined with ChIP-seq analyses exclude an indirect function for *EOMES*. Finally, *Mixl1* remains expressed—albeit at low levels—in *Eomes* mutant mouse embryos, demonstrating that *Mixl1* expression is not sufficient to rescue DE specification in the absence of *Eomes* in vivo (Arnold et al. 2008). Nevertheless, *EOMES* and *MIXL1* may still collaborate to control the expression of a broad number of DE genes. Further analyses, including *MIXL1* ChIP-seq, may support this hypothesis.

Our results reveal that *EOMES* function in hESCs resembles, in many aspects, maternal *VegT* in *Xenopus* (Xanthos et al. 2001), and thus that *EOMES* may be the functional mammalian homolog of this “master” regulator. Of interest, recent studies demonstrate that *EOMES* interacts with SMAD2/3 to control the expression of mesoderm markers in *Xenopus* (Picozzi et al. 2009). This implies that *EOMES* function in germ layer specification has been redirected during evolution to replace *VegT*, while its direct interaction with Activin/Nodal signaling has been conserved. Our results also suggest that, in contrast to *VegT*, *EOMES* acts as a transcriptional repressor on mesoderm genes, and thus plays a critical role in the balance between endoderm and mesoderm differentiation. The capacity for *EOMES* to repress pluripotency markers represents another function not shared by *VegT*. Indeed, *EOMES* appears necessary to extinguish the expression of *OCT4*, *SOX2*, and *NANOG* in vivo, suggesting the existence of a negative feedback loop. Thus, *EOMES* has not only evolved functionally, but also has acquired new activities specific to

mammalian development, including termination of the pluripotency program.

Importantly, our results in hESCs are strikingly different from those obtained using similar approaches in mESCs. Functional studies in mESCs have shown that *Eomes*, *Oct4*, *Sox2*, and *Nanog* control extraembryonic tissue (primitive endoderm and trophoblast) specification, whereas these same TFs control germ layer development in hESCs (Vallier et al. 2009a). This apparent contradiction can be explained by the different embryonic identities of mESCs and hESCs/mEpiSCs, both of which share a common pool of pluripotency factors (*OCT4*, *SOX2*, and *NANOG*) (Boyer et al. 2005; Loh et al. 2006). This implies that the transcriptional network maintaining pluripotency constantly evolves during early development to allow the specification of new tissues, and that specific factors are constantly up-regulated and down-regulated to control this process. The identities of these additional factors are largely unknown, but recent reports identify *Sall4*, *Klf4*, and *Tbx3* as potential candidates, since they are specifically expressed in mESCs and control early extraembryonic fate (Lim et al. 2008; Hall et al. 2009; Niwa et al. 2009). Furthermore, direct comparison of the transcriptional network characterizing mESCs, hESCs, and mEpiSCs will permit us to uncover the key changes in the mechanisms controlling pluripotency during implantation in mammals.

In conclusion, our insights into the function of *EOMES* and *NANOG* in DE specification show how pluripotency factors and master regulators of differentiation can cooperate with extracellular growth factors such as Activin/Nodal signaling to direct early cell fate decisions during mammalian development. They also reveal that the function of the Activin/Nodal signaling pathway is defined by the presence of specific SMAD2/3 partners, which can either maintain pluripotency or induce differentiation.

Materials and methods

Cell culture

H9 hESCs (WiCell) and 129/SvJ mEpiSCs were cultured in CDM with 10 ng/mL Activin A and 12 ng/mL FGF2 as described previously (Brons et al. 2007). hESCs and mEpiSCs were induced to differentiate into endoderm using CDM-PVA + 100 ng/mL Activin + 10 ng/mL BMP4 + 20 ng/mL FGF2 + 10 μ M LY294002 (Promega) (Touboul et al. 2010). Ten micromolar Alk4/5/7 inhibitor SB431542 (Tocris Bioscience) (Inman et al. 2002) was used in place of Activin on days 1, 2, and 3. Cells were then harvested accordingly.

Transfection

Transfections were performed with Lipofectamine 2000 as described previously (Vallier et al. 2004). Construct details are provided in the Supplemental Material.

RT-qPCR, immunostaining, FACS, and Western blot analyses

Methods for RT-qPCR, immunostaining, FACS, and Western blot analyses have been described previously (Vallier et al. 2005, 2009a; Brons et al. 2007). All error bars indicate standard deviation of three biological replicates in at least two independent

experiments. qPCR primers and antibodies used for immunostaining, FACS, and Western blot analyses are provided in Supplemental Table 7.

Microarray profiling

Microarray profiling was performed as described previously (Touboul et al. 2010). Additional details are found in the Supplemental Material. Briefly, total RNA was extracted using RNeasy Mini Kit according to the manufacturer's protocol (Qiagen). RNA samples were first assessed for their integrity prior to microarray hybridization. Five biological replicates for each condition among undifferentiated and day 1, day 2, and day 3 differentiated hESCs were hybridized to Illumina Human Ref-8 version 3.0 Expression BeadChips according to the manufacturer's protocol. In addition, four biological replicate samples of both shScrambled-hESC and shEOMES-hESC clones were hybridized to Illumina Human Ref-8 version 3.0 Expression BeadChips. Raw data were processed and analyzed for differential expression as described in the Supplemental Material.

ChIP-seq

ChIP was carried out as described in the Supplemental Material followed by qPCR using SYBR green (SensiMix Quantace). Antibodies and primers are provided in Supplemental Table 7. Results were either expressed as relative pull-down amount when quantitated against the standard curve drawn using input DNA or normalized against a control region (−10,157 to −10,055 bases upstream of *SOX17* start codon) (data not shown), and fold change was calculated between antibody pull down and IgG control. Data are representative of three experiments and error bars indicate standard deviation of three biological replicates. For ChIP-seq, libraries were prepared using the Solexa ChIP-seq DNA sample prep kit (IP102-1001). After amplification, DNA fragments between 180 and 400 base pairs (bp) were gel-extracted and sent for sequencing. Libraries were sequenced by Geneservice (<http://www.geneservice.co.uk>) and Beckman Coulter Genomics using the Illumina Genome Analyzer II. Raw data were uploaded to Gene Expression Omnibus with accession number GSE26097.

Luciferase assays

A fragment of the hEOMES enhancer region (−6943 to −6090) was subcloned into the pGL3-Promoter vector (Promega), and the resulting construct was cotransfected into hESCs with pCMV-Renilla (Promega) and overexpression vectors (pTP6-NANOG, pTP6-OCT4, and pTP6-SOX2) using Lipofectamine 2000 according to the manufacturer's protocol (Invitrogen). Luciferase activity was then measured using the Dual-Luciferase Reporter Assay System (Promega). Firefly luciferase activity was normalized to renilla luciferase activity, and results were expressed as relative expression normalized against hrGFP control.

WISH

WISH was carried out as described previously (Nagy et al. 2003).

Acknowledgments

We thank Morgan Alexander for her support in cell culture reagents, Candy Cho and Dr. Nick Hannan for FACS analyses, Sarah Draeger for help with the WISH, and Drs. Patrick Tam, Brigid Hogan, Phil Soriano, and Tristan Rodriguez for providing WISH probes. A.K.K.T., L.T.A., and Z.C. are supported by the A*STAR Graduate Academy (Singapore). S.J.A. is supported by

the Emmy Noether-Program of the DFG, M.W.B.T. is supported by an MRC center grant, and L.V. is supported by an MRC senior fellowship and the Cambridge Hospitals National Institute for Health Research Biomedical Research Center.

References

- Arnold SJ, Robertson EJ. 2009. Making a commitment: Cell lineage allocation and axis patterning in the early mouse embryo. *Nat Rev Mol Cell Biol* **10**: 91–103.
- Arnold SJ, Hofmann UK, Bikoff EK, Robertson EJ. 2008. Pivotal roles for eomesodermin during axis formation, epithelium-to-mesenchyme transition and endoderm specification in the mouse. *Development* **135**: 501–511.
- Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R. 2003. Multipotent cell lineages in early mouse development depend on SOX2 function. *Genes Dev* **17**: 126–140.
- Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, et al. 2005. Core transcriptional regulatory circuitry in human embryonic stem cells. *Cell* **122**: 947–956.
- Brons IG, Smithers LE, Trotter MW, Rugg-Gunn P, Sun B, Chuva de Sousa Lopes SM, Howlett SK, Clarkson A, Ahrlund-Richter L, Pedersen RA, et al. 2007. Derivation of pluripotent epiblast stem cells from mammalian embryos. *Nature* **448**: 191–195.
- Chew JL, Loh YH, Zhang W, Chen X, Tam WL, Yeap LS, Li P, Ang YS, Lim B, Robson P, et al. 2005. Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. *Mol Cell Biol* **25**: 6031–6046.
- Chng Z, Teo A, Pedersen RA, Vallier L. 2010. SIP1 mediates cell-fate decisions between neuroectoderm and mesendoderm in human pluripotent stem cells. *Cell Stem Cell* **6**: 59–70.
- Conlon FL, Fairclough L, Price BM, Casey ES, Smith JC. 2001. Determinants of T box protein specificity. *Development* **128**: 3749–3758.
- D'Amour KA, Agulnick AD, Eliazar S, Kelly OG, Kroon E, Baetge EE. 2005. Efficient differentiation of human embryonic stem cells to definitive endoderm. *Nat Biotechnol* **23**: 1534–1541.
- Davis S, Miura S, Hill C, Mishina Y, Klingensmith J. 2004. BMP receptor IA is required in the mammalian embryo for endodermal morphogenesis and ectodermal patterning. *Dev Biol* **270**: 47–63.
- Downs KM. 2008. Systematic localization of Oct-3/4 to the gastrulating mouse conceptus suggests manifold roles in mammalian development. *Dev Dyn* **237**: 464–475.
- Dufort D, Schwartz L, Harpal K, Rossant J. 1998. The transcription factor HNF3 β is required in visceral endoderm for normal primitive streak morphogenesis. *Development* **125**: 3015–3025.
- Greber B, Wu G, Bernemann C, Joo JY, Han DW, Ko K, Tapia N, Sabour D, Sterneckert J, Tesar P, et al. 2010. Conserved and divergent roles of FGF signaling in mouse epiblast stem cells and human embryonic stem cells. *Cell Stem Cell* **6**: 215–226.
- Hall J, Guo G, Wray J, Eyres I, Nichols J, Grotewold L, Morfopoulou S, Humphreys P, Mansfield W, Walker R, et al. 2009. Oct4 and LIF/Stat3 additively induce Kruppel factors to sustain embryonic stem cell self-renewal. *Cell Stem Cell* **5**: 597–609.
- Hart AH, Hartley L, Sourris K, Stadler ES, Li R, Stanley EG, Tam PP, Elefanty AG, Robb L. 2002. Mixl1 is required for axial mesendoderm morphogenesis and patterning in the murine embryo. *Development* **129**: 3597–3608.
- Hart AH, Hartley L, Ibrahim M, Robb L. 2004. Identification, cloning and expression analysis of the pluripotency promoting Nanog genes in mouse and human. *Dev Dyn* **230**: 187–198.

- Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. 2002. SB-431542 is a potent and specific inhibitor of transforming growth factor- β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. *Mol Pharmacol* **62**: 65–74.
- Izumi N, Era T, Akimaru H, Yasunaga M, Nishikawa S. 2007. Dissecting the molecular hierarchy for mesendoderm differentiation through a combination of embryonic stem cell culture and RNA interference. *Stem Cells* **25**: 1664–1674.
- Kanai-Azuma M, Kanai Y, Gad JM, Tajima Y, Taya C, Kurohmaru M, Sanai Y, Yonekawa H, Yazaki K, Tam PP, et al. 2002. Depletion of definitive gut endoderm in Sox17-null mutant mice. *Development* **129**: 2367–2379.
- Lim CY, Tam WL, Zhang J, Ang HS, Jia H, Lipovich L, Ng HH, Wei CL, Sung WK, Robson P, et al. 2008. Sall4 regulates distinct transcription circuitries in different blastocyst-derived stem cell lineages. *Cell Stem Cell* **3**: 543–554.
- Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, Bourque G, George J, Leong B, Liu J, et al. 2006. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. *Nat Genet* **38**: 431–440.
- Lunde K, Belting HG, Driever W. 2004. Zebrafish pou5f1/pou2, homolog of mammalian Oct4, functions in the endoderm specification cascade. *Curr Biol* **14**: 48–55.
- Martello G, Zacchigna L, Inui M, Montagner M, Adorno M, Mamidi A, Morsut L, Soligo S, Tran U, Dupont S, et al. 2007. MicroRNA control of Nodal signalling. *Nature* **449**: 183–188.
- Mesnard D, Guzman-Ayala M, Constam DB. 2006. Nodal specifies embryonic visceral endoderm and sustains pluripotent cells in the epiblast before overt axial patterning. *Development* **133**: 2497–2505.
- Morkel M, Huelsken J, Wakamiya M, Ding J, van de Wetering M, Clevers H, Taketo MM, Behringer RR, Shen MM, Birchmeier W. 2003. β -Catenin regulates Cripto- and Wnt3-dependent gene expression programs in mouse axis and mesoderm formation. *Development* **130**: 6283–6294.
- Nagy A, Gertsenstein M, Vintersten K, Behringer R. 2003. *Manipulating the mouse embryo: A laboratory manual* (3rd ed.). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- Niwa H, Miyazaki J, Smith AG. 2000. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. *Nat Genet* **24**: 372–376.
- Niwa H, Ogawa K, Shimosato D, Adachi K. 2009. A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. *Nature* **460**: 118–122.
- Picozzi P, Wang F, Cronk K, Ryan K. 2009. Eomesodermin requires transforming growth factor- β /activin signaling and binds Smad2 to activate mesodermal genes. *J Biol Chem* **284**: 2397–2408.
- Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A. 2000. Embryonic stem cell lines from human blastocysts: Somatic differentiation in vitro. *Nat Biotechnol* **18**: 399–404.
- Rivera-Perez JA, Mallo M, Gendron-Maguire M, Gridley T, Behringer RR. 1995. Goosecoid is not an essential component of the mouse gastrula organizer but is required for craniofacial and rib development. *Development* **121**: 3005–3012.
- Rosa A, Spagnoli FM, Brivanlou AH. 2009. The miR-430/427/302 family controls mesendodermal fate specification via species-specific target selection. *Dev Cell* **16**: 517–527.
- Russ AP, Wattler S, Colledge WH, Aparicio SA, Carlton MB, Pearce JJ, Barton SC, Surani MA, Ryan K, Nehls MC, et al. 2000. Eomesodermin is required for mouse trophoblast development and mesoderm formation. *Nature* **404**: 95–99.
- Tesar PJ, Chenoweth JG, Brook FA, Davies TJ, Evans EP, Mack DL, Gardner RL, McKay RD. 2007. New cell lines from mouse epiblast share defining features with human embryonic stem cells. *Nature* **448**: 196–199.
- Thiery JP, Sleeman JP. 2006. Complex networks orchestrate epithelial–mesenchymal transitions. *Nat Rev Mol Cell Biol* **7**: 131–142.
- Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. 1998. Embryonic stem cell lines derived from human blastocysts. *Science* **282**: 1145–1147.
- Touboul T, Hannan NR, Corbinea S, Martinez A, Martinet C, Branchereau S, Mainot S, Strick-Marchand H, Pedersen R, Di Santo J, et al. 2010. Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. *Hepatology* **51**: 1754–1765.
- Vallier L, Reynolds D, Pedersen RA. 2004. Nodal inhibits differentiation of human embryonic stem cells along the neuroectodermal default pathway. *Dev Biol* **275**: 403–421.
- Vallier L, Alexander M, Pedersen RA. 2005. Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. *J Cell Sci* **118**: 4495–4509.
- Vallier L, Mendjan S, Brown S, Chng Z, Teo A, Smithers LE, Trotter MW, Cho CH, Martinez A, Rugg-Gunn P, et al. 2009a. Activin/Nodal signalling maintains pluripotency by controlling Nanog expression. *Development* **136**: 1339–1349.
- Vallier L, Touboul T, Brown S, Cho C, Bilican B, Alexander M, Cedervall J, Chandran S, Ahrlund-Richter L, Weber A, et al. 2009b. Signaling pathways controlling pluripotency and early cell fate decisions of human induced pluripotent stem cells. *Stem Cells* **27**: 2655–2666.
- Vallier L, Touboul T, Chng Z, Brimpari M, Hannan N, Millan E, Smithers LE, Trotter M, Rugg-Gunn P, Weber A, et al. 2009c. Early cell fate decisions of human embryonic stem cells and mouse epiblast stem cells are controlled by the same signalling pathways. *PLoS ONE* **4**: e6082. doi: 10.1371/journal.pone.0006082.
- Vincent SD, Dunn NR, Hayashi S, Norris DP, Robertson EJ. 2003. Cell fate decisions within the mouse organizer are governed by graded Nodal signals. *Genes Dev* **17**: 1646–1662.
- Xanthos JB, Kofron M, Wylie C, Heasman J. 2001. Maternal VegT is the initiator of a molecular network specifying endoderm in *Xenopus laevis*. *Development* **128**: 167–180.
- Xu RH, Sampsell-Barron TL, Gu F, Root S, Peck RM, Pan G, Yu J, Antosiewicz-Bourget J, Tian S, Stewart R, et al. 2008. NANOG is a direct target of TGF β /activin-mediated SMAD signaling in human ESCs. *Cell Stem Cell* **3**: 196–206.

Pluripotency factors regulate definitive endoderm specification through eomesodermin

Adrian Kee Keong Teo, Sebastian J. Arnold, Matthew W.B. Trotter, et al.

Genes Dev. 2011, **25**: originally published online January 18, 2011
Access the most recent version at doi:[10.1101/gad.607311](https://doi.org/10.1101/gad.607311)

Supplemental Material

<http://genesdev.cshlp.org/content/suppl/2011/01/10/gad.607311.DC1>

References

This article cites 44 articles, 16 of which can be accessed free at:
<http://genesdev.cshlp.org/content/25/3/238.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).